Sudarshan Pharma Industries Ltd Q2 FY26 — ₹591 Cr Sales, ₹19.5 Cr PAT, ₹1500 Cr Fundraise on Horizon: The Chemical Love Story That Refuses To Dilute
1. At a Glance
Ladies and gentlemen, meet Sudarshan Pharma Industries Ltd (SPIL) — the company that’s turning solvents into solvency and acids into assets. Listed on the BSE SME with a market cap of ₹647 crore, SPIL’s current price of ₹26.9 is just about one-third of its 52-week high of ₹53.5 — the stock seems to have gone on its own detox program.
Despite the hangover, the company has posted Sales of ₹591 crore (TTM) and PAT of ₹19.5 crore, with ROE at 14.8% and ROCE at 15.5% — not bad for a chemical-pharma hybrid that also moonlights as a solvent trader.
Debt, however, has ballooned faster than a balloon at a kids’ birthday — ₹219 crore on the books, taking the Debt/Equity ratio to 1.56. Yet, management dreams big: $15 million FCCBs, ₹1,500 crore fundraise, and new units sprouting in Gujarat, Palghar, and abroad.
The company’s quarterly numbers? Q2 FY26 clocked ₹168.9 crore revenue and ₹3.87 crore PAT — down 38% QoQ, proving pharma cycles have more mood swings than a teenager.
But wait — they’ve just won a ₹9.19 crore legal award in Dubai, bagged PLI approval worth ₹115 crore incentives, and are setting up Vitamin B1/B6 units to replace Chinese imports. So — genius in disguise, or chemistry experiment gone wild? Let’s dissect.
2. Introduction
In a world full of boring, white-coat pharma giants, Sudarshan Pharma walks in wearing sunglasses, carrying a test tube in one hand and a spreadsheet in the other.
Born in 2008, the company plays multiple roles — manufacturer, trader, exporter, acquirer, litigant, and, occasionally, magician (because how else do you explain making ₹591 crore sales and still paying zero dividends?).
They make APIs, formulations, and fancy chemicals with names that sound like alien cocktails — Acetonitrile, DMF, DMSO, and Hydrogen Hydride. Their product list reads like a chemistry viva question paper designed to scare engineers.
In true Indian startup style, they’re expanding everywhere — Bangladesh, Lebanon, Ghana, even Uzbekistan (because why not?). Add a PLI project with ₹86 crore investment and new cardiac kits called “Heart Kit LD” and “Heart Kit 4” — and you realize SPIL is trying to become the Tata Motors of APIs — experimenting in every possible direction.
So, should we clap for their ambition or call the auditor? Let’s investigate.
3. Business Model — WTF Do They Even Do?
Sudarshan Pharma’s business model can be described as “chemistry with chaos.”
They do jobwork manufacturing for pharma products, trade chemicals and solvents, and also develop formulations under 56 registered brands like Love Birds, Metfocal, and Pulmo Relief. Yes, you read that right — Love Birds — apparently, nothing says “romance” like a branded antibiotic.
They straddle three worlds:
Speciality Chemicals: Solvents and intermediates used in pharma and industrial manufacturing — basically the building blocks of drugs.
APIs (Active Pharmaceutical Ingredients): The actual molecules that make drugs work. They’re even producing critical import substitutes (Vitamin B1 and B6).
Formulations: Finished medicines — the stuff you actually swallow after reading “shake well before use.”
And when not cooking up molecules, they’re busy expanding — a new Palghar plant, a greenfield Gujarat facility under PLI, and two foreign subsidiaries in Canada and the US.
It’s like a smallcap with a split personality: half pharma scientist, half chemical trader, fully optimistic.
But hey, optimism is a business model in India. Just ask Paytm.
